Gap junction enhancer as an anti-cancer agent via GJIC-independent and -dependent pathways

K-REx Repository

Show simple item record

dc.contributor.author Ding, Ying
dc.date.accessioned 2013-04-30T17:25:40Z
dc.date.available 2013-04-30T17:25:40Z
dc.date.issued 2013-04-30
dc.identifier.uri http://hdl.handle.net/2097/15705
dc.description.abstract Gap junctions (GJ) are intercellular channels connecting adjacent cells, allowing small molecules to transport between cells, thereby maintaining all homeostasis. Loss of gap junctional intercellular communication (GJIC) and/or connexins, the gap junction proteins, is a hallmark of cancer. Restoration of GJIC and/or increase of connexin expression have been related to the reduction of tumorigenesis. Connexins have been reported as tumor suppressors due to both GJIC-independent and -dependent mechanisms. Therefore, development of effective agents or methods to enhance GJIC and restore connexin expression in cancer cells is a new strategy in cancer treatment. PQ1, 6-Methoxy-8-[(3-aminopropyl)amino]-4-methyl-5-(3-trifluoromethyl-phenyloxy)quinoline, has been demonstrated to increase GJIC, restore connexin expression, and exert anti-cancer effects on T47D breast cancer cells. Studies of apoptotic pathways showed that PQ1 activated both extrinsic and intrinsic apoptotic pathways, indicating that PQ1 exerts its anti-cancer effects via a GJIC-independent mechanism through the induction of apoptosis. Combinational treatment of PQ1 and cisplatin showed that PQ1 counteracted cisplatin-induced inhibition of GJIC and reduction of connexin expression, thereby increasing the efficacy of cisplatin in T47D cancer cells via a GJIC-dependent mechanism. Further studies of drug distribution and toxicity revealed that administration of PQ1 by oral gavage can be achieved with low toxicity to normal vital organs. All the results suggest that PQ1, a gap junction enhancer, can function as an anti-cancer agent and potentiate the efficacy of antineoplastic drugs via both GJIC-independent and -dependent pathways. en_US
dc.language.iso en_US en_US
dc.publisher Kansas State University en
dc.subject Gap junction en_US
dc.subject Breast cancer en_US
dc.subject PQ1 en_US
dc.subject Quinoline derivative en_US
dc.title Gap junction enhancer as an anti-cancer agent via GJIC-independent and -dependent pathways en_US
dc.type Dissertation en_US
dc.description.degree Doctor of Philosophy en_US
dc.description.level Doctoral en_US
dc.description.department Department of Biochemistry and Molecular Biophysics en_US
dc.description.advisor Thu Annelise Nguyen en_US
dc.subject.umi Biochemistry (0487) en_US
dc.subject.umi Molecular Biology (0307) en_US
dc.date.published 2013 en_US
dc.date.graduationmonth May en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search K-REx


Advanced Search

Browse

My Account

Statistics








Center for the

Advancement of Digital

Scholarship

cads@k-state.edu